Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammato...
Website: fortressbiotech.com



Growth: Bad revenue growth rate -25.0%, there is slowdown compared to average historical growth rates 7.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -69.0%.

Cash Flow Generation: Dividend yield for the last twelve months 29.2%. Free cash flow yield 7.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 15.2% higher than minimum and 76.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -2.0x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FBIOP
Share price, USD:  (-0.5%)5.76
year average price 8.79  


year start price 16.74 2024-04-03

max close price 17.50 2024-04-12

min close price 5.00 2024-10-15

current price 5.76 2025-04-02
Common stocks: 19 697 290

Dividend Yield:  29.2%
EV / Sales: 1.9x
Margin (EBITDA LTM / Revenue): -69.0%
Fundamental value created in LTM:
Market Cap ($m): 118
Net Debt ($m): -6
EV (Enterprise Value): 112
Price to Book: 5.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-07-05globenewswire.com

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-14 2024-08-13 2024-05-15 2024-03-28 2023-09-30 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-11
acceptedDate 2024-11-14 16:40:34 2024-08-13 16:30:43 2024-05-15 16:32:08 2024-03-28 16:49:36 2023-09-29 20:00:00 2023-08-14 16:16:03 2023-05-15 16:16:26 2023-03-31 16:05:28 2022-11-14 16:16:37 2022-08-11 16:08:08
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 15M 15M 13M 20M 35M 17M 12M 16M 17M 19M
costOfRevenue 5M 7M 7M 6M 6M 8M 6M 8M 7M 8M
grossProfit 9M 8M 6M 14M 28M 10M 6M 9M 9M 11M
grossProfitRatio 0.639 0.561 0.477 0.68 0.815 0.553 0.481 0.53 0.563 0.596
researchAndDevelopmentExpenses 9M 13M 25M 14M 20M 32M 40M 35M 30M 33M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 22M 21M 18M 19M 22M 24M 25M 28M 30M 29M
otherExpenses 0 3M -21 000 -1M 620 000 395 000 -351 000 -635 000 -669 000 0
operatingExpenses 31M 36M 43M 33M 42M 57M 64M 63M 59M 62M
costAndExpenses 37M 43M 50M 40M 49M 64M 71M 70M 67M 70M
interestIncome 589 000 734 000 833 000 707 000 547 000 715 000 1M 687 000 419 000 150 000
interestExpense 6M 2M -3M 2M 2M 5M 3M 3M 3M 3M
depreciationAndAmortization 3M 1M 2M 2M 3M 1M 2M 2M 2M 2M
ebitda -21M -26M -37M -18M -10M -46M -56M -52M -48M -17M
ebitdaratio -1.44 -1.755 -2.806 -0.9 -0.302 -2.64 -4.507 -3.197 -2.896 -0.876
operatingIncome -22M -28M -37M -20M -14M -50M -59M -54M -50M -51M
operatingIncomeRatio -1.51 -1.865 -2.806 -0.986 -0.396 -2.882 -4.708 -3.292 -3.029 -2.696
totalOtherIncomeExpensesNet -5M -1M 19M -9M 5M -7M 3M -3M -3M -3M
incomeBeforeTax -27M -29M -18M -29M -11M -59M -55M -57M -53M -54M
incomeBeforeTaxRatio -1.82 -1.935 -1.361 -1.434 -0.305 -3.411 -4.437 -3.475 -3.21 -2.856
incomeTaxExpense 69 000 0 -2M 379 000 141 000 -29M -33M 449 000 -31M 0
netIncome -13M -11M -18M -9M -5M -25M -22M -57M -23M -21M
netIncomeRatio -0.88 -0.735 -1.361 -0.465 -0.145 -1.425 -1.779 -3.502 -1.363 -1.131
eps -0.76 -0.73 -1.03 -0.86 -10.09 -3.36 -0.22 -0.65 -0.25 -0.24
epsdiluted -0.76 -0.73 -1.03 -0.86 -10.09 -3.36 -0.22 -0.65 -0.25 -0.24
weightedAverageShsOut 20M 18M 17M 11M 499 910 7M 102M 89M 89M 89M
weightedAverageShsOutDil 20M 18M 17M 11M 499 910 7M 102M 89M 89M 89M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-14 2024-08-13 2024-05-15 2024-03-28 2023-09-30 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-11
acceptedDate 2024-11-14 16:40:34 2024-08-13 16:30:43 2024-05-15 16:32:08 2024-03-28 16:49:36 2023-09-29 20:00:00 2023-08-14 16:16:03 2023-05-15 16:16:26 2023-03-31 16:05:28 2022-11-14 16:16:37 2022-08-11 16:08:08
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 59M 76M 86M 81M 72M 78M 152M 178M 208M 249M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 59M 76M 86M 81M 72M 78M 152M 178M 208M 249M
netReceivables 11M 11M 10M 15M 8M 17M 28M 28M 29M 29M
inventory 12M 10M 11M 10M 11M 12M 13M 14M 15M 16M
otherCurrentAssets 5M 7M 10M 11M 6M 7M 8M 10M 6M 5M
totalCurrentAssets 86M 103M 117M 117M 98M 128M 202M 230M 258M 299M
propertyPlantEquipmentNet 18M 18M 23M 23M 24M 25M 32M 33M 34M 32M
goodwill 0 0 0 0 0 0 0 0 0 0
intangibleAssets 18M 19M 19M 20M 21M 22M 26M 27M 28M 29M
goodwillAndIntangibleAssets 18M 19M 19M 20M 21M 22M 26M 27M 28M 29M
longTermInvestments 0 0 2M 2M 2M 2M 0 0 0 0
taxAssets 0 0 0 0 -2M -2M 0 0 0 0
otherNonCurrentAssets 5M 5M 4M 4M 7M 6M 3M 4M 4M 3M
totalNonCurrentAssets 41M 42M 48M 51M 53M 53M 61M 64M 66M 65M
otherAssets 0 0 0 0 0 0 0 0 0 0
totalAssets 127M 146M 165M 168M 151M 181M 264M 294M 324M 364M
accountPayables 34M 38M 42M 35M 45M 49M 66M 57M 56M 54M
shortTermDebt 4M 5M 10M 9M 5M 15M 10M 13M 11M 10M
taxPayables 850 000 806 000 843 000 843 000 84 000 0 722 000 1M 0 345 000
deferredRevenue 0 23M 843 000 843 000 37M 51M 547 000 728 000 1M 1M
otherCurrentLiabilities 32M 31M 35M 40M 10M 15M 53M 57M 38M 40M
totalCurrentLiabilities 70M 76M 88M 85M 97M 129M 129M 128M 106M 105M
longTermDebt 68M 83M 61M 61M 65M 66M 112M 115M 114M 109M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 2M 2M 19M 20M 2M 2M 2M 2M 48M 2M
totalNonCurrentLiabilities 70M 85M 81M 81M 66M 68M 114M 117M 116M 111M
otherLiabilities 0 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 18M 18M 18M 18M 21M 22M 24M 24M 24M 22M
totalLiabilities 140M 160M 169M 166M 164M 197M 244M 244M 222M 216M
preferredStock 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000
commonStock 28 000 23 000 19 000 15 000 9000 155 000 130 000 110 000 108 000 108 000
retainedEarnings -734M -721M -710M -695M -686M -681M -656M -634M -607M -585M
accumulatedOtherComprehensiveIncomeLoss 0 0 -3000 -15 000 0 -3000 0 0 0 0
othertotalStockholdersEquity 755M 739M 733M 717M 702M 699M 693M 676M 669M 662M
totalStockholdersEquity 21M 18M 23M 23M 17M 19M 38M 42M 62M 77M
totalEquity -13M -15M -4M 2M -13M -16M 20M 42M 62M 77M
totalLiabilitiesAndStockholdersEquity 127M 146M 165M 168M 151M 181M 264M 294M 324M 293M
minorityInterest -34M -32M -27M -21M -30M -34M -18M 8M 0 0
totalLiabilitiesAndTotalEquity 127M 146M 165M 168M 151M 181M 264M 294M 324M 293M
totalInvestments 0 2M 2M 2M 2M 2M 0 0 0 0
totalDebt 72M 88M 89M 89M 70M 81M 123M 127M 125M 119M
netDebt 13M 12M 3M 8M -2M 3M -30M -51M -83M -130M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP FBIOP
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-14 2024-08-13 2024-05-15 2024-03-28 2023-09-30 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-11
acceptedDate 2024-11-14 16:40:34 2024-08-13 16:30:43 2024-05-15 16:32:08 2024-03-28 16:49:36 2023-09-29 20:00:00 2023-08-14 16:16:03 2023-05-15 16:16:26 2023-03-31 16:05:28 2022-11-14 16:16:37 2022-08-11 16:08:08
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -13M -11M -15M -9M -11M -59M -55M -57M -53M -54M
depreciationAndAmortization -3M 1M 2M 2M 3M 1M 2M 3M 2M 2M
deferredIncomeTax 0 0 0 -21M -5M 10M 0 0 0 0
stockBasedCompensation 0 5M 5M 4M 4M 4M 5M 6M 7M 5M
changeInWorkingCapital -5M -3M 6M -18M -8M 8M 6M 1M -267 000 4M
accountsReceivables -12M -712 000 5M -7M 9M 10M 466 000 51 000 83 000 2M
inventory -519 000 893 000 -374 000 818 000 1M 1M 881 000 1M 823 000 84 000
accountsPayables 6M -6M 3M -7M -17M -4M 5M 4M 0 0
otherWorkingCapital 686 000 2M -2M -4M -784 000 549 000 25 000 -4M -1M -577 000
otherNonCashItems 585 000 -14M -21M 8M 76 000 3M -1M 490 000 874 000 1M
netCashProvidedByOperatingActivities -20M -22M -25M -35M -17M -33M -43M -48M -43M -41M
investmentsInPropertyPlantAndEquipment 0 0 0 -63 000 -1M -34 000 0 -391 000 -1M -307 000
acquisitionsNet 0 0 0 -6M 6M 5M -5M 20M 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 -35 000 5M -7M 0 -20M 127 000 0
netCashUsedForInvestingActivites 0 0 0 -63 000 5M -2M -5M -391 000 -893 000 -307 000
debtRepayment -17M 5M 0 -15M -10M -43M -28M -2M 0 0
commonStockIssued 21M 16M 30M 32M 10M 15M 24M 18M 2M 5M
commonStockRepurchased 0 0 0 -400 000 90 000 88 000 0 -1M 0 0
dividendsPaid -176 000 -2M -2M -2M -2M -2M -2M -2M -2M -2M
otherFinancingActivites -501 000 -4M 30M 97 000 -979 000 -5000 29M 6M 4M 193 000
netCashUsedProvidedByFinancingActivities 3M 14M 28M 44M -3M -30M 22M 19M 4M 3M
effectOfForexChangesOnCash 0 0 0 -2M 0 0 0 0 0 0
netChangeInCash -17M -8M 5M 6M -14M -66M -26M -30M -40M -39M
cashAtEndOfPeriod 61M 78M 86M 81M 75M 89M 155M 181M 211M 251M
cashAtBeginningOfPeriod 78M 86M 81M 75M 89M 155M 181M 211M 251M 290M
operatingCashFlow -20M -22M -25M -35M -17M -33M -43M -48M -43M -41M
capitalExpenditure 0 0 0 -63 000 -1M -34 000 0 -391 000 -1M -307 000
freeCashFlow -20M -22M -25M -35M -18M -33M -43M -48M -44M -42M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-03-31 00:00 ET
Fortress Biotech published news for 2024 q4
SEC form 8
2025-03-31 00:00 ET
Fortress Biotech reported for 2024 q4
SEC form 10
2025-03-31 00:00 ET
Fortress Biotech published news for 2024 q4
SEC form 8
2024-11-14 00:00 ET
Fortress Biotech published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Fortress Biotech published news for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Fortress Biotech reported for 2024 q3
SEC form 8
2024-08-13 00:00 ET
Fortress Biotech published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Fortress Biotech published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Fortress Biotech reported for 2024 q2
SEC form 8
2024-05-15 00:00 ET
Fortress Biotech published news for 2024 q1
SEC form 8
2024-05-15 00:00 ET
Fortress Biotech published news for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Fortress Biotech reported for 2024 q1
SEC form 10
2024-03-28 00:00 ET
Fortress Biotech reported for 2023 q4
SEC form 10
2023-11-14 00:00 ET
Fortress Biotech reported for 2023 q3
SEC form 8
2023-11-14 00:00 ET
Fortress Biotech published news for 2023 q3
SEC form 8
2023-08-14 00:00 ET
Fortress Biotech published news for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Fortress Biotech reported for 2023 q2
SEC form 10
2023-05-15 00:00 ET
Fortress Biotech published news for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Fortress Biotech reported for 2023 q1
SEC form 6
2023-04-13 16:05 ET
Fortress Biotech published news for 2023 q1
SEC form 10
2023-03-31 16:05 ET
Fortress Biotech reported for 2022 q4
SEC form 10
2023-03-31 00:00 ET
Fortress Biotech reported for 2022 q4
SEC form 6
2023-03-30 17:28 ET
Fortress Biotech published news for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Fortress Biotech reported for 2022 q4
SEC form 6
2023-03-13 17:28 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-03-03 16:55 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-02-09 17:03 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-06 18:40 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-06 17:57 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:27 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:26 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:25 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:25 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:24 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:24 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2023-01-04 21:23 ET
Fortress Biotech published news for 2022 q4
SEC form 6
2022-12-19 08:49 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-12-19 08:26 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-11-14 17:02 ET
Fortress Biotech published news for 2022 q3
SEC form 10
2022-11-14 16:16 ET
Fortress Biotech reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Fortress Biotech reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Fortress Biotech reported for 2022 q3
SEC form 6
2022-11-04 16:06 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-10-28 16:58 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-10-24 08:00 ET
Fortress Biotech published news for 2022 q3
SEC form 6
2022-08-25 16:02 ET
Fortress Biotech published news for 2022 q2
SEC form 6
2022-08-11 16:46 ET
Fortress Biotech published news for 2022 q2
SEC form 10
2022-08-11 16:08 ET
Fortress Biotech reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Fortress Biotech reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Fortress Biotech reported for 2022 q2
SEC form 6
2022-07-22 16:01 ET
Fortress Biotech published news for 2022 q2
SEC form 6
2022-07-11 16:00 ET
Fortress Biotech published news for 2022 q2
SEC form 6
2022-06-27 16:52 ET
Fortress Biotech published news for 2022 q1
SEC form 10
2022-05-12 16:18 ET
Fortress Biotech reported for 2022 q1
SEC form 6
2022-05-12 16:16 ET
Fortress Biotech published news for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Fortress Biotech reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Fortress Biotech reported for 2022 q1
SEC form 6
2022-04-29 17:37 ET
Fortress Biotech published news for 2022 q1
SEC form 6
2022-04-20 17:00 ET
Fortress Biotech published news for 2022 q1
SEC form 10
2022-03-28 16:06 ET
Fortress Biotech published news for 2021 q4
SEC form 6
2022-03-28 08:16 ET
Fortress Biotech published news for 2021 q4
SEC form 10
2022-03-28 00:00 ET
Fortress Biotech published news for 2021 q4
SEC form 8
2022-03-28 00:00 ET
Fortress Biotech published news for 2021 q4
SEC form 6
2021-12-07 08:01 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-11-15 16:15 ET
Fortress Biotech published news for 2021 q3
SEC form 10
2021-11-15 16:06 ET
Fortress Biotech published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Fortress Biotech published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-10-27 08:16 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-10-06 16:14 ET
Fortress Biotech published news for 2021 q3
SEC form 6
2021-09-29 07:45 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-09-28 16:10 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-09-24 17:19 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-08-27 17:02 ET
Fortress Biotech published news for 2021 q2
SEC form 10
2021-08-16 16:14 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-08-16 16:08 ET
Fortress Biotech published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Fortress Biotech published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-07-29 17:01 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-07-14 19:17 ET
Fortress Biotech published news for 2021 q2
SEC form 6
2021-06-23 16:15 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-06-17 16:21 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-05-17 16:21 ET
Fortress Biotech published news for 2021 q1
SEC form 10
2021-05-17 16:07 ET
Fortress Biotech published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
Fortress Biotech published news for 2021 q1
SEC form 8
2021-05-17 00:00 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-30 16:02 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-20 16:16 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-13 17:13 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-09 17:29 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-04-01 07:00 ET
Fortress Biotech published news for 2021 q1
SEC form 6
2021-03-31 16:21 ET
Fortress Biotech published news for 2020 q4
SEC form 10
2021-03-31 16:03 ET
Fortress Biotech published news for 2020 q4
SEC form 6
2021-02-24 08:15 ET
Fortress Biotech published news for 2020 q4
SEC form 6
2020-11-09 16:37 ET
Fortress Biotech published news for 2020 q3
SEC form 10
2020-11-09 16:07 ET
Fortress Biotech published news for 2020 q3